Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337124 · ClinicalTrials.gov registry record
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
A clinical trial, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- 229
- Enrollment target
NCT05337124: Completed study, sponsored by Aurinia Pharmaceuticals.
NCT05337124 is a clinical trial that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 229 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05337124 has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- 229 participants
- Enrollment target
Study Summary
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
Primary Outcome
The proportion of patients that had their first Urine Protein Creatinine Ratio (UPCR) \>0.5 mg within 6 months of initiating LUPKYNIS.
Interventions
- DRUG LUPKYNIS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-01-31 |
What the finished NCT05337124 record still lists
NCT05337124 is an observational study that tracks outcomes without assigning an intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which LUPKYNIS is the first listed.
NCT05337124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05337124 about?
NCT05337124 is a clinical study titled "A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US". This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
What is the current status of trial NCT05337124?
This trial is currently completed. The enrollment target is 229 participants. The study started on 2022-04-05. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05337124?
The interventions under investigation include: LUPKYNIS (DRUG).
Who is sponsoring clinical trial NCT05337124?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI